Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules. 2005

Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
Department of Experimental Pathology and Oncology, University of Florence, Italy.

To provide some insight into molecular mechanisms of 5 fluorouracil (5-FU) clinical resistance in colorectal cancer, we hypothesized that different in vitro exposure schedules of human colorectal cancer cell lines mimicking clinical infusion or bolus regimens could lead to differential gene expression. Resistant HCT-8 colon cancer cell lines (HCT-8/FUI/15R and HCT-8/FUB/2R) were selected from parental sensitive HCT-8 cells by long-term and short-term exposure schedules, respectively. Expression levels of the 437 genes evaluated by the Atlas Select cDNA Expression Human Tumor Array were not substantially different between HCT-8/FUB/2R and HCT-8 cell lines except for three genes downregulated in the resistant subline. Several genes were differentially expressed in HCT-8/FUI/15R cells compared to the parental cell line: 43 genes, including three chemoresistance-related genes, were upregulated, and three genes were downregulated. HCT-8/FUB/2R cells were substantially more resistant to 5-FU in comparison to HCT-8/FUI/15R cells after both 4- and 72-h exposures. No substantial differences were observed among resistant and parental cells in sensitivity to SN-38, the active metabolite of irinotecan, and oxaliplatin. Analysis of the mRNA levels of thymidylate synthase, thymidine phosphorylase, and bcl-2 genes evaluated by reverse transcription and real time PCR (RT-PCR) assay showed comparable results in resistant sublines and sensitive parental cells, whereas expression of the dihydropyrimidine dehydrogenase gene was markedly increased in both resistant cell lines compared to parental cells.

UI MeSH Term Description Entries
D011061 Poly A A group of adenine ribonucleotides in which the phosphate residues of each adenine ribonucleotide act as bridges in forming diester linkages between the ribose moieties. Adenine Polynucleotides,Polyadenylic Acids,Poly(rA),Polynucleotides, Adenine
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077146 Irinotecan A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS. 7-Ethyl-10-hydroxycamptothecin,CPT 11,CPT-11,Camptosar,Camptothecin-11,Irinotecan Hydrochloride,Irrinotecan,NK012 Compound,SN 38,SN 38 11,SN-38,SN-38-11,7 Ethyl 10 hydroxycamptothecin,CPT11,Camptothecin 11,SN3811
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
January 2019, BioMed research international,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
April 1992, Cancer research,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
January 2008, Chemotherapy,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
April 2012, International journal of oncology,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
May 1995, Biochemical pharmacology,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
March 1989, European journal of cancer & clinical oncology,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
March 1993, Biochemical pharmacology,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
March 1997, Biochemical pharmacology,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
February 1995, Biochemical pharmacology,
Alessio Tempestini, and Barbara Caciagli, and Maria Morganti, and Ewa Witort, and Stefania Nobili, and Laura Papucci, and Nicola Schiavone, and Martino Donnini, and Ida Landini, and Andrea Lapucci, and Federico Perna, and Matteo Lulli, and Teresita Mazzei, and Alberto Sobrero, and Enrico Mini, and Sergio Capaccioli
October 2007, International journal of colorectal disease,
Copied contents to your clipboard!